We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for enasidenib (Celgene Pty Ltd)
Active ingredients
enasidenib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
For the treatment of patients with acute myeloid leukaemia with an isocitrate dehydrogenase-2 (IDH2) mutation.